Anhedonia is a reduced ability to feel pleasure — including from food — that some people report on GLP-1 medications alongside appetite and reward changes, and that's worth raising with a prescriber if it persists.
Updated Sep 26, 2026
Anhedonia is a diminished ability to experience pleasure, including from previously enjoyable activities like eating. Because GLP-1 medications act on brain reward and dopamine pathways to reduce hedonic (pleasure-driven) eating, some patients report a broader blunting of enjoyment beyond food. This effect is an active area of research, and anyone experiencing persistent low mood, loss of interest, or reduced enjoyment of life should discuss it with their prescriber — it can be a sign to reassess dose or treatment. Our guide on getting mental health support on a GLP-1 covers what to watch for and how to find help.
Existing article recorded at the start of version history
Improve this page▾
Community notes
Share helpful experiences and questions. Notes are reviewed before publication and do not replace medical advice.
Loading notes…
New submissions are currently paused. Existing approved notes remain available.
Related terms
Cognitive behavioral therapy — A structured, time-limited form of talk therapy (CBT) that works on the links between thoughts, feelings, and behaviors, with strong evidence for anxiety, depression, insomnia, and binge eating.
Generalized anxiety disorder (GAD) — A mental health condition marked by persistent, excessive, hard-to-control worry about many things over months, often with restlessness, tension, and poor sleep.
Binge eating disorder (BED) — An eating disorder involving recurrent episodes of eating large amounts of food with a sense of loss of control, and distress afterward — without compensatory purging.
Related guides
GLP-1 medications and depression: what the evidence shows, and what to watch — Do GLP-1 medications cause depression? The best evidence says no increase in the randomized trials, and in January 2026 the FDA asked for the suicidal-ideation warning to come off the Saxenda, Wegovy and Zepbound labels. Some real-world studies still find a small depression signal, depending on what the drug is compared with, and the months after stopping deserve attention. The drug isn't a depression treatment either. This guide covers the evidence on both sides, what to watch, and when to get help.
GLP-1 medications and anxiety: what the evidence shows, and what to watch — Do GLP-1 medications cause anxiety? Large trial data say no overall increase: a 2026 meta-analysis of 86 randomized trials found no link, and the FDA's January 2026 review of 91 trials found no rise in anxiety or other psychiatric events. People still vary. Most stay stable, some feel calmer, and a minority develop new or worse anxiety. It is not a treatment for anxiety. This guide covers the evidence, what to monitor, and when to get help.
Getting mental health support while on a GLP-1: finding a therapist and the challenges to name — Losing weight on a GLP-1 changes more than your body. Appetite, self-image, coping habits, and how others treat you can all shift, sometimes faster than your mind catches up. This practical guide covers the mental-health challenges people commonly face on these medications, the kinds of professionals who can help, how to find and afford one, and the crisis resources to keep close.